Literature DB >> 25855882

Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on Statins.

Martin Krsak1, David M Kent2,3, Norma Terrin3,4, Christina Holcroft1, Sally C Skinner1, Christine Wanke1.   

Abstract

Despite combination antiretroviral therapy (cART), people living with HIV (PLWH) continue to have more systemic inflammation and metabolic disturbances than the general population. These risk factors for atherosclerosis and organ dysfunction may be ameliorated by statins. We retrospectively analyzed 438 cART treated PLWH from the Nutrition For Healthy Living (NFHL) cohort to determine the association between statins and myocardial infarction (MI), stroke, and all-cause mortality as a composite. We used Cox proportional hazards regression as our main analysis. The average age was 44 years, 32% were women, and 67 of the 438 subjects used statins. There was no association between statins and our composite endpoint in two separate models [1.26 (0.57-2.79) in statin history model and 0.93 (0.65-1.32) per year in statin duration model]. The composite outcome was significantly associated with CD4 count, age, and smoking status in both models. CD4 count remained significant even after exclusion of mortality from the composite (HR=0.88, p=0.02). Confounding control via propensity scoring and multiple imputations did not change the results. Statins did not have an effect on MI, stroke, and mortality. Interestingly, CD4 count appears to be an important predictor of these outcomes, even after exclusion of death from the composite.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25855882      PMCID: PMC4516911          DOI: 10.1089/apc.2014.0309

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  25 in total

1.  Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy.

Authors:  Laura Galli; Stefania Salpietro; Gabriele Pellicciotta; Alberto Galliani; Piermarco Piatti; Hamid Hasson; Monica Guffanti; Nicola Gianotti; Alba Bigoloni; Adriano Lazzarin; Antonella Castagna
Journal:  Eur J Epidemiol       Date:  2012-06-22       Impact factor: 8.082

Review 2.  The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.

Authors:  Mohamed H Ahmed; Ayman Al-Atta; Mahir A Hamad
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

3.  Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.

Authors:  A Mocroft; C A Sabin; M Youle; S Madge; M Tyrer; H Devereux; J Deayton; A Dykhoff; M C Lipman; A N Phillips; M A Johnson
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-15       Impact factor: 3.731

4.  Markers of atherosclerosis and inflammation and mortality in patients with HIV infection.

Authors:  Alexandra Mangili; Joseph F Polak; Lien A Quach; Jul Gerrior; Christine A Wanke
Journal:  Atherosclerosis       Date:  2010-11-17       Impact factor: 5.162

5.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

6.  Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.

Authors:  Jason V Baker; Jacqueline Neuhaus; Daniel Duprez; Lewis H Kuller; Russell Tracy; Waldo H Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel E Nixon; Nicholas I Paton; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

7.  Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.

Authors:  David R Boulware; Katherine Huppler Hullsiek; Camille E Puronen; Adam Rupert; Jason V Baker; Martyn A French; Paul R Bohjanen; Richard M Novak; James D Neaton; Irini Sereti
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

8.  Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy.

Authors:  Hamish McManus; Catherine C O'Connor; Mark Boyd; Jennifer Broom; Darren Russell; Kerrie Watson; Norman Roth; Phillip J Read; Kathy Petoumenos; Matthew G Law
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.

Authors:  Richard D Moore; John G Bartlett; Joel E Gallant
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240

Review 10.  Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.

Authors:  Alexios S Antonopoulos; Marios Margaritis; Regent Lee; Keith Channon; Charalambos Antoniades
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

View more
  9 in total

Review 1.  Infection and Stroke: an Update on Recent Progress.

Authors:  Eliza C Miller; Mitchell S V Elkind
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

Review 2.  Benefits and Risks of Statin Therapy in the HIV-Infected Population.

Authors:  Mosepele Mosepele; Onkabetse J Molefe-Baikai; Steven K Grinspoon; Virginia A Triant
Journal:  Curr Infect Dis Rep       Date:  2018-05-26       Impact factor: 3.725

3.  Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease.

Authors:  Joshua A Beckman; Meredith S Duncan; Charles W Alcorn; Kaku So-Armah; Adeel A Butt; Matthew Bidwell Goetz; Hilary A Tindle; Jason J Sico; Russel P Tracy; Amy C Justice; Matthew S Freiberg
Journal:  Circulation       Date:  2018-03-13       Impact factor: 29.690

4.  High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda.

Authors:  Daniel Muyanja; Conrad Muzoora; Anthony Muyingo; Winnie Muyindike; Mark J Siedner
Journal:  AIDS Patient Care STDS       Date:  2015-12-18       Impact factor: 5.078

5.  Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Patient Care STDS       Date:  2018-02       Impact factor: 5.078

Review 6.  Pathophysiology and management of cardiovascular disease in patients with HIV.

Authors:  Eric Nou; Janet Lo; Colleen Hadigan; Steven K Grinspoon
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-10       Impact factor: 32.069

7.  Consistent use of lipid lowering therapy in HIV infection is associated with low mortality.

Authors:  Henning Drechsler; Colby Ayers; James Cutrell; Reuben Arasaratnam; Roger Bedimo
Journal:  BMC Infect Dis       Date:  2021-02-05       Impact factor: 3.090

8.  Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis.

Authors:  Olalekan A Uthman; Chidozie Nduka; Samuel I Watson; Edward J Mills; Andre P Kengne; Shabbar S Jaffar; Aileen Clarke; Tahereh Moradi; Anna-Mia Ekström; Richard Lilford
Journal:  BMC Infect Dis       Date:  2018-06-05       Impact factor: 3.090

Review 9.  HIV-associated cardiovascular disease: importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies.

Authors:  Jeffrey Laurence; Sonia Elhadad; Jasimuddin Ahamed
Journal:  Open Heart       Date:  2018-07-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.